PAR-28-062-Full-Announcement.html

Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s)

National Institutes of Health (NIH)

Components of Participating Organizations

NATIONAL CANCER INSTITUTE (NCI)

Note: Not all NIH Institutes, Centers, and Offices (ICOs) participate in Announcements. Applicants should carefully note which ICOs participate in this announcement and view their respective areas of research interest at the ICO-Specific Scientific Interests website. ICOs that do not participate in this announcement will not consider applications for funding.

Funding Opportunity Title

Cancer Advancement through Partnerships in Research and Infrastructure (CAPRI) (U54 Clinical Trial Optional)

Activity Code

U54 Specialized Center- Cooperative Agreements

Announcement Type

Reissue of

PAR-22-249

Related Notices

Funding Opportunity Number (FON)

PAR-28-062

Companion Notice of Funding Opportunity

None

Number of Applications

See Section III. 3. Additional Information on Eligibility.

Assistance Listing Number(s)

93.399

Notice of Funding Opportunity Purpose

This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that invites applications from eligible organizations to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the applications will be peer-reviewed, and only meritorious applications will be considered for funding. This funding opportunity seeks to support the Cancer Advancement through Partnerships in Research and Infrastructure (CAPRI). The CAPRI Program establishes and strengthens comprehensive, mutually beneficial and meaningful partnerships between Resource Limited Institutions (RLIs) and NCI-designated Cancer Centers (CCs) to accelerate collaborative and innovative cancer. The Program achieves this by strategically building institutional capacity, advancing research capabilities, enhancing the impact of innovative cancer research, cultivating the next generation of Early-Stage Investigators and trainees, and implementing coordinated outreach and education initiatives that extend the benefits of research to all populations nationwide.

Funding Opportunity Goal(s)

To reduce cancer risk, incidence, morbidity, and mortality and enhance quality of life in cancer survivors through an orderly sequence from research on interventions and their impact in defined populations to the broad, systematic application of the research results through dissemination and diffusion strategies.

Key Dates

Posted Date

August 31, 2026

Open Date (Earliest Submission Date)

December 25, 2026

The following table includes NIH standard due dates marked with an asterisk.

January 25, 2027 *

January 25, 2027 *

Not Applicable

December 2027

All applications are due by 5:00 PM local time of applicant organization.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date

January 26, 2027

Due Dates for E.O. 12372

Not Applicable

Required Application Instructions

It is critical that applicants follow the Multi-Project (M) Instructions in the How to Apply - Application Guide, except where instructed to do otherwise (in this NOFO or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the How to Apply - Application Guide and the NOFO) is required and strictly enforced. Applicants must read and follow all application instructions in the How to Apply - Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the How to Apply - Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.

Table of Contents

Part 1. Overview Information Key Dates Part 2. Full Text of Announcement Section I. Notice of Funding Opportunity Description Section II. Award Information Section III. Eligibility Information Section IV. Application and Submission Information Section V. Application Review Information Section VI. Award Administration Information Section VII. Agency Contacts Section VIII. Other Information

Part 2. Full Text of Announcement

Section I. Notice of Funding Opportunity Description

Purpose The NCI conducts and supports research, training, health information dissemination, and other programs concerning cancer. This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that invites applications from eligible organizations to apply (please see Section III. Eligibility for additional information). In accordance with NIH standard peer-review processes, the applications will be peer-reviewed, and only meritorious applications will be considered for funding. This funding opportunity seeks to support the Cancer Advancement through Partnerships in Research and Infrastructure (CAPRI) Program. The purpose of the CAPRI Program is to establish and strengthen comprehensive and mutually beneficial partnerships between Resource Limited Institutions (RLIs) and NCI-designated Cancer Centers (CCs) to accelerate collaborative and innovative cancer. Through strategic capacity building, CAPRI supports the development and expansion of sustainable research programs at partnering institutions, enhances the quality and competitiveness of cancer research programs, and promotes the integration of complementary expertise and resources across institutions. Joint research projects conducted primarily at RLIs may span any area of cancer research and are intended to strengthen institutional research capacity and scientific productivity. The program further advances the career development of Early-Stage Investigators (ESIs) and trainees to cultivate a robust cancer research workforce and supports coordinated outreach and education activities that align with and reinforce the partnership's research objectives. Collectively, these efforts are designed to generate impactful cancer research discoveries and extend their benefits nationwide.

Through its emphasis on scientific excellence, collaborative research, and community-focused engagement, this funding opportunity advances workforce development, and national efforts to reduce the burden of cancer and improve health outcomes. In doing so, CAPRI aligns with broader Administration priorities, including the Make America Healthy Again (MAHA) initiative, by strengthening the nation's research enterprise and accelerating progress toward improved health and well-being for all populations across the United States.

The institutions in each partnership are expected to work collaboratively to:

To underscore their commitment to the partnership, linked applications from each partnering institution are required.

Background A disproportionate burden of cancer exists among many population groups and geographic regions. Therefore, expanding our cancer knowledge across populations is critical to control this devastating disease. There is a critical need to expand biomedical research capacity and opportunities at RLIs, particularly in regions with low NIH participation. Strengthening RLIs is key to broadening the national cancer research enterprise, fostering innovation, and building sustainable, competitive research programs. Through structured collaboration with CCs, the CAPRI Program accelerates the development of research infrastructure and scientific capacity at RLIs, expands access to specialized expertise and shared resources, and positions these institutions to compete for external funding and lead impactful cancer research initiatives.

CCs are distinguished by rigorous programs across basic, clinical, translational, and population sciences, along with strong leadership and workforce development. Partnerships with RLIs extend the reach of their research, and enhance engagement with broader communities. These collaborations create mutual benefits: RLIs build research capacity and develop investigators, while CCs expand the reach and impact of their research. Together, they serve as a national model for advancing innovation and addressing complex cancer challenges.

For this funding announcement, to qualify as an RLI, institutions must:

CAPRI as a Partnership Program The CAPRI Program builds capacity through collaborative partnerships that leverage the strengths of RLIs and CCs. Joint research, shared resources, and coordinated training strengthen research environments and expand cancer programs at RLIs. These collaborations provide access to advanced technologies, expertise, mentorship, and training for ESIs, supporting sustainable programs and improving competitiveness for external funding. Overall, CAPRI enhances scientific capacity, advances cancer research, and supports long-term workforce growth. The CAPRI Program supports ESIs and trainees through mentorship, research training, and professional development within the partnerships. Participation in collaborative research provides experience in multidisciplinary settings and builds skills in study design, data analysis, communication, and grant writing. These structured opportunities prepare investigators to compete for external funding and strengthen the national cancer research workforce.

CAPRI supports innovative research projects that leverage the complementary strengths of RLIs and CCs to build capacity and productivity. Joint research projects conducted primarily at RLIs may span all areas of cancer research.Partnerships are encouraged to address the needs of their catchment populations across the lifespan and may include basic, clinical, translational, prevention, behavioral, and population research, as well as emerging technologies, precision medicine, clinical trials, and outreach efforts, all of which align with NCI's priorities. Hypothesis-driven outreach research projects are also appropriate, including those aimed at increasing high-quality, clinically annotated biospecimens from populations representative of the partnering institutions' catchment area. The goal is to generate preliminary data to support competitive R01-level applications and strengthen research capacity at RLIs.

CAPRI is designed to promote improved health outcomes for all Americans while advancing research focused on populations that experience a disproportionate burden of cancer. These efforts will also strengthen research capacity and support evidence-based approaches to improve cancer outcomes nationwide.

Research support: This partnership program provides support for cancer research infrastructure and not to exceed three years support for research projects.

Research Team: The PD(s)/PI(s) are expected to be mid-to-senior-level scientists with records of obtaining grant support and serving as role models and mentors. A less experienced investigator can be one of multiple PDs/PIs if there is an appropriate institutional investment in this investigator and a demonstrable collaboration (active or planned) with a more experienced PD/PI.

Community outreach and engagement are integral to CAPRI and its key function involves supporting the partnership's research efforts. Partnerships will implement coordinated outreach and education initiatives to strengthen community connections, raise awareness of cancer prevention and care, and support participation in research. These efforts help translate scientific discoveries into practical strategies while ensuring research remains responsive to community needs.

Each partnership program is expected to include:

1. Administrative Core: will provide day-to-day administrative support for the partnership, ensuring bidirectional and integral collaborations across institutions.

2. Full and Pilot Research Projects: each new or competing renewal application should propose at least one Full Research Project and one Pilot Research Project.

3. Planning and Evaluation Core: provides continuous process, outcomes, and impact planning and evaluation of partnership activities.

4. Outreach and Engagement Core: provides support and is aligned with the partnership's cancer research and includes bidirectional activities to develop and share targeted educational materials with surrounding communities.

5. Shared Resources: applicants may propose the development of resources/infrastructure that augments the cancer research capability of the RLIs, the collaborative research of both partnering institutions, and/or enhance cancer research.

It is expected that all activities should be planned to:

Through integrated efforts in collaborative research, capacity building, workforce development, and community engagement, the CAPRI Program aims to strengthen partnerships between RLIs and CCs and advance the national cancer research enterprise.

Internal Evaluation Each partnership must have an Internal Advisory Committee (IAC). The IAC is shared across the partnering institutions and will have an equal numerical composition of qualified faculty members from the partnering institutions (See Section VI Terms and Conditions of Award). The IAC is responsible for the internal evaluation of the partnership's activities.

IAC will evaluate ongoing and proposed pilots, full projects, and project concepts under development. This evaluation may occur once a year or as needed. The following scenarios are possible: (1) convert pre-pilot to pilot, (2) pilot to a full project, or (3) terminate funding of pilot and/or full project.

External Evaluation, Scientific Feedback, and Guidance The Program Steering Committee (PSC) is an external committee of investigators from non-partnering institutions (See Section VI. Terms and Conditions of Award), provides annual evaluation, scientific feedback, and guidance. It reviews progress, assesses ongoing and proposed projects, and collaborates with NCI on final decisions. The PSC meets annually, ideally in person, to conduct a comprehensive evaluation.

Assessing Program Outcomes The success of the CAPRI Program will be assessed based on metrics directly linked to the partnership's objectives. Moreover, each partnership should develop logic models for the overall partnership and each core. Metrics will include, but not limited to, increased infrastructure support at the RLIs and faculty conducting cancer research. Metrics at the CCs will include, but not be limited to, increased cancer research.In addition, an increased number of cancer-related education and awareness outreach and engagement activities to surrounding communities, and the development of community partnerships. The Program may promote the participation of individuals from all populations in cancer clinical trials and bio-specimen donation by developing and implementing innovative methodologies. Partnerships are encouraged to leverage CRCHD's community outreach toolkits and the U54 Outreach Evaluation Toolkit developed by the U54 Evaluation Task Force Evaluators. Each partnership should also identify metrics tailored to their specific goals.

Non-Responsive Applications Applicants are encouraged to contact the NOFO scientific/research contact before submission to discuss whether their application is responsive.

Investigators proposing NIH-defined clinical trials may refer to the Research Methods Resources website for information about developing statistical methods and study designs.

See Section VIII. Other Information for award authorities and regulations.

Section II. Award Information

Funding Instrument

Cooperative Agreement: A financial assistance mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this NOFO.

Application Types Allowed

New

Renewal

Resubmission

The OER Glossary and the How to Apply - Application Guide provides details on these application types. Only those application types listed here are allowed for this NOFO.

Clinical Trial?

Optional: Accepting applications that either propose or do not propose clinical trial(s).

Need help determining whether you are doing a clinical trial?

Funds Available and Anticipated Number of Awards

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Award Budget

Application budgets are limited to $1.3 million in direct costs per year for partnerships of two institutions and $1.8 million in direct costs per year for partnerships of three institutions.

Award Project Period

The maximum period is 5 years.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.

Section III. Eligibility Information

1. Eligible Applicants

Eligible Organizations

Nonprofits Other Than Institutions of Higher Education

For-Profit Organizations

Federal Governments

Eligible Agencies of the Federal Government

U.S. Territory or Possession

Each partnership must include both types of institutions: 1) RLIs, and 2) NCI-designated Cancer Center (CC). Partnerships involving more than two institutions require NCI approval before applying.

RLIs with medical schools or with more focused education and research programs (e.g., Master's and PhD programs), as well as those that offer only Baccalaureate degrees and Tribal Colleges, may all participate in this initiative.

For this funding announcement, to qualify as an RLI, institutions must:

Foreign Organizations/International Collaborations

Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Required Registrations

Applicant organizations Applicant organizations must complete and maintain the following registrations as described in the How to Apply- Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of a due date is not a valid reason for a late submission, please reference NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications for additional information.

System for Award Management (SAM) – Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code. Foreign organizations must obtain a NATO Commercial and Government Entity (NCAGE) Code (in lieu of a CAGE code) in order to register in SAM. Unique Entity Identifier (UEI)- A UEI is issued as part of the SAM.gov registration process. The same UEI must be used for all registrations, as well as on the grant application.

Program Directors/Principal Investigators (PD(s)/PI(s)) All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. Obtaining an eRA Commons account can take up to 2 weeks.

All PD(s)/PI(s) must be registered with ORCID. The personal profile associated with the PD(s)/PI(s) eRA Commons account must be linked to a valid ORCID ID. For more information on linking an ORCID ID to an eRA Commons personal profile see the ORCID topic in our eRA Commons online help.

Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the How to Apply - Application Guide.

This NOFO supports linked applications. Multiple PDs/PIs are allowed on any single application.

Specific to this NOFO:

2. Cost Sharing This NOFO does not require cost sharing as defined in the NIH Grants Policy Statement Section 1.2- Definitions of Terms.

3. Additional Information on Eligibility Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time per NIH Grants Policy Statement Section 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:

A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.

A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.

An application that has substantial overlap with another application pending appeal of initial peer review (see NIH Grants Policy Statement 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Please note that specifically for this NOFO, the NCI will support only one U54 partnership for each institution.

Section IV. Application and Submission Information

1. Requesting an Application Package The application forms package specific to this opportunity must be accessed through ASSIST or an institutional system-to-system solution. A button to apply using ASSIST is available in Part 1 of this NOFO. See the administrative office for instructions if planning to use an institutional system-to-system solution.

2. Content and Form of Application Submission It is critical that applicants follow the Multi-Project (M) Instructions in the How to Apply - Application Guide, except where instructed in this notice of funding opportunity to do otherwise (in this NOFO, in a policy notice, or other notice from NIH Guide for Grants and Contracts) and where instructions in the How to Apply - Application Guide are directly related to the Grants.gov downloadable forms currently used with most NIH opportunities. Conformance to the requirements in the How to Apply - Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

Page Limitations All page limitations described in the How to Apply- Application Guide and the Table of Page Limits must be followed.

Required

Required

Required

Required

Required

Required

Optional

NA

Instructions for the Submission of Multi-Component Applications

The following section supplements the instructions found in How to Apply- Application Guide and should be used for preparing a multi-component application.

Overall Component When preparing the application, use Component Type 'Overall'.

All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions, as noted.

SF424(R&R) Cover (Overall) Complete entire form.

PHS 398 Cover Page Supplement (Overall) Follow standard instructions.

Research & Related Other Project Information (Overall) Follow standard instructions.

Project Summary/Abstract: Provide overall goals/abstract/summary for the entire partnership application.

Project Narrative: In the "Project Narrative," state the relevance of the research to the partnership objectives and, in lay language, the relevance of the partnership's research to public health.

Facilities and Other Resources:

Describe resources available for the partnership. This description should include the allocation of space and facilities, provisions for capital improvements, etc., for new projects/programs of the partnership.

Institutional Investment in the Success of Less-Experienced Investigators: For each Early-Stage Investigator (ESI) or other less-experienced investigators involved as PDs/PIs or leads/co-leads on the application components, describe institutional investment in the success of the investigator. Specifically, the elements covered by the "Institutional Investments" should be well-matched to the individual investigator's research objectives and the ability to compete for independent peer review funding.

Given these general objectives for "Institutional Investments," document the following aspects:

Other Attachments: The following "Other Attachments" must be included with the overall component to aid in the review of applications. The filename provided for each attachment will be the name used for the bookmark in the application image.

Performance Assessment: Renewal applications must include the assessment of their U54 partnerships by their respective Program Steering Committees (PSCs).

RLI Statement: Any institution applying as an RLI must include a statement signed by an institution's official certifying it is eligible as an RLI in the application.

Project/Performance Site Locations (Overall) Enter primary site only.

A summary of Project/Performance Sites in the Overall section of the assembled application image in eRA Commons compiled from data collected in the other components will be generated upon submission.

Research and Related Senior/Key Person Profile (Overall) Include only the Project Director/Principal Investigator (PD/PI) and any multi-PDs/PIs (if applicable to this NOFO) for the entire application.

A summary of Senior/Key Persons followed by their Biographical Sketches in the Overall section of the assembled application image in eRA Commons will be generated upon submission.

Budget (Overall) The only budget information included in the Overall component is the Estimated Project Funding section of the SF424 (R&R) Cover.

A budget summary in the Overall section of the assembled application image in eRA Commons compiled from detailed budget data collected in the other components will be generated upon submission.

PHS 398 Research Plan (Overall) Introduction to Application: For Resubmission and Revision applications, an Introduction to Application is required in the Overall component.

Specific Aims: State the objectives of the collaboration. Outline the overall goals relevant to providing support for investigators at both the RLI and CC to conduct cancer research and other related activities. Specific Aims must be identical for both collaborative applications.

Research Strategy: The application from each site must contain a research strategy that describes the aspects of the project that are common to all sites in the collaboration. All variations in the Research Strategy between sites, no matter how minor, should be highlighted in a subsection of the Research Strategy with the heading "Elements Unique to This Site."

Outline the following aspects:

Note (and address accordingly) the following expectations for the partnership research and other activities:

Educational activities and outreach activities are also encouraged.

In outlining the plans for all these activities, explain how these collective efforts will be aimed at securing competitively funded extramural research awards. Specify your target expectations (e.g., R01, P50 awards, or projects on P01 or their equivalents). Small grants are also desirable, as a step in the career advancement of ESI.

Progress Report (for Renewal Applications only): Summarize the accomplishments and progress during the current funding period for specific partnership components (Administrative Core; Research Projects/Programs; Outreach Core; Shared Resources; and Evaluation Activities) in the context of the goals described in the original U54 application. For example, applicants may present a chronological history of their partnerships, discuss barriers faced, and indicate how these obstacles were resolved. Mention significant administrative changes that took place, name faculty members supported by the U54 award, and list grants (including the funding organization and type of award), the number of students or postdocs participating in research projects, where the participants are, etc., resulting from the U54 award. Discuss how recommendations of the PSC, IAC, and leadership have influenced the partnership activities. It is strongly recommended that a table be included summarizing all grants and publications resulting from the funded pilot, full projects, and programs.

Planning Activities (for new applications only): Provide documentation that this partnership was derived from careful planning and priority-setting processes based on each partnering institution's strengths/weaknesses. Describe the outcomes of the planning process relevant to the proposed partnership in response to this NOFO.

In chronological order, present each process used in planning and setting the priorities and objectives for this application. Briefly describe the nature of each planning activity, its purpose, the individuals who participated from both institutions, and its outcome.

Progress Report Publication List (for Renewal Applications): Include only the publications and accepted manuscripts from projects conducted during the current funding period. Mark each listed publication that results from the different projects within the partnership.

Letters of Support: Each application must include Letters of Support from the respective leadership of each institution (e.g., President, Cancer Center Director, Dean) to show support for the partnership and commitment to additional resources necessary to ensure that these partnerships will have the maximum sustainability. Specifically, institutional leaders are expected to provide detailed statements of the long-term commitment and list the specific resources, space, investigators' protected time, etc. Identify the number of investigators dedicated to cancer research under the partnership.

Letters of Support should include the following specific items:

When the PD/PI from the RLI or CC does not have experience as a PD/PI on a peer-reviewed grant, there must be a Letter of Support from a senior member (e.g., Department Chair, Dean, Cancer Center Director) of the RLI or CC indicating his/her qualifications and the willingness to guide and mentor the inexperienced PD/PI and support her/his research and academic development.

Resource Sharing Plan:

Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the How to Apply - Application Guide.

Other Plan(s):

All instructions in the How to Apply- Application Guide must be followed, with the following additional instructions:

A Data Management and Sharing Plan (DMS Plan) is required for any NIH-funded or conducted research that will generate scientific data. Applicants must submit the DMS Plan at the time of application using the NIH DMS Plan Format Page. The DMS Plan must address the elements in the structured format. Where the DMS Plan Format Page requires a "Yes or No" response, no additional narrative is allowed. The Data Management and Sharing (DMS) Plan must be provided in the Overall component.

Appendix:

Only limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in How to Apply- Application Guide; any instructions provided here are in addition to the How to Apply - Application Guide instructions.

PHS Human Subjects and Clinical Trials Information (Overall) When involving human subjects research, clinical research, and/or NIH-defined clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the How to Apply - Application Guide, with the following additional instructions:

If you answered "Yes" to the question "Are Human Subjects Involved?" on the R&R Other Project Information form, there must be at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record within the application. The study record(s) must be included in the component(s) where the work is being done, unless the same study spans multiple components. To avoid the creation of duplicate study records, a single study record with sufficient information for all involved components must be included in the Overall component when the same study spans multiple components.

Study Record: PHS Human Subjects and Clinical Trials Information All instructions in the How to Apply - Application Guide must be followed.

Delayed Onset Study

Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the How to Apply- Application Guide must be followed.

PHS Assignment Request Form (Overall) All instructions in the How to Apply- Application Guide must be followed.

Administrative Core When preparing your application, use Component Type 'Admin Core.' All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.

SF424 (R&R) Cover (Administrative Core) Complete only the following fields:

PHS 398 Cover Page Supplement (Administrative Core) Follow standard instructions.

Research & Related Other Project Information (Administrative Core) Human Subjects: Answer only the 'Are Human Subjects Involved?' and 'Is the Project Exempt from Federal regulations?' questions.

Vertebrate Animals: Answer only the 'Are Vertebrate Animals Used?' question.

Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment, indicating it is required. However, eRA systems only enforce this requirement in the Overall component, and applications will not receive an error if omitted in other components.

Project /Performance Site Location(s) (Administrative Core) List all performance sites that apply to the specific component.

Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachments for additional entries.

Research & Related Senior/Key Person Profile (Administrative Core)

Budget (Administrative Core) Budget forms appropriate for the specific component will be included in the application package.

Administrative costs (new applications may have higher administrative costs in the early stage of development and lower in the late stages) for managing the planning effort, such as salaries for Administrative Core key personnel, travel for key personnel (e.g., costs related to attendance at an annual CAPRIworkshop), equipment, and supplies to support an administrative structure.

Effort Commitments: Individuals designated as PD(s)/PI(s) are expected to be committed to the partnership for effective leadership. U54 CAPRIapplications are multiple PI-based, according to the requirements that the PD/PI from the RLI must be listed as PD/PI on the CC U54 application and vice versa, with "in-kind" effort. Specifically, a minimum of 1.2 person-months (with a maximum of 3 person-months) effort per year is expected for the contact PD/PI from the RLI and Cancer Center. In each institution, for all the other PD(s)/PI(s) combined, the total effort per year is limited to 6 months for the RLI and 4.8 months for the CC.

Budget Justification: Justify all the costs associated with this core. Administrative Core will provide funding for managing the partnership, such as: salaries for key personnel, equipment, and supplies to support an administrative structure.

Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.

PHS 398 Research Plan (Administrative Core) Introduction to Application: F or Resubmission applications only.

Specific Aims: Succinctly describe the specific objectives and goals of the Administrative Core.

Research Strategy: The Administrative Core must have the appropriate organizational structure to support the partnership's cancer research, research education, and community outreach and engagement efforts. To achieve this, there must be effective planning, communication, and continuous evaluation of partnership activities.

The applications must describe the administrative structure of the partnership to concisely address the following:

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification: Resource Sharing Plans should only be included in the Overall component of the application.

Other Plan(s):

All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

Do not include a Data Management and Sharing (DMS) Plan within this Component. If a DMS Plan is required for this NOFO, it must be included within the Overall Component.

Appendix: Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.

PHS Human Subjects and Clinical Trials Information (Administrative Core) When involving human subjects research, clinical research, and/or NIH-defined clinical trials, follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

If you answered "Yes" to the question "Are Human Subjects Involved?" on the R&R Other Project Information form, there must be at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record within the application. The study record(s) must be included in the component(s) where the work is being done unless the same study spans multiple components. To avoid the creation of duplicate study records, a single study record with sufficient information for all involved components must be included in the Overall component when the same study spans multiple components.

Study Record: PHS Human Subjects and Clinical Trials Information All instructions in the SF424 (R&R) Application Guide must be followed.

Delayed Onset Study Note: Delayed Onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the SF424 (R&R) Application Guide must be followed.

Full Research Project When preparing your application in ASSIST, use Component Type 'Project.' All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.

SF424 (R&R) Cover (Full Research Project) Complete only the following fields:

PHS 398 Cover Page Supplement (Full Research Project) Follow standard instructions.

Research & Related Other Project Information (Full Research Project) Human Subjects: Answer only the 'Are Human Subjects Involved?' and 'Is the Project Exempt from Federal regulations?' questions.

Vertebrate Animals: Answer only the 'Are Vertebrate Animals…